Linda Watkins
Concepts (964)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperalgesia | 70 | 2024 | 123 | 11.660 |
Why?
| | Neuralgia | 40 | 2024 | 133 | 11.200 |
Why?
| | Toll-Like Receptor 4 | 46 | 2023 | 273 | 8.360 |
Why?
| | Pain | 61 | 2021 | 756 | 7.730 |
Why?
| | Microglia | 55 | 2024 | 251 | 7.300 |
Why?
| | Rats, Sprague-Dawley | 240 | 2024 | 2487 | 6.870 |
Why?
| | Spinal Cord | 50 | 2023 | 370 | 6.140 |
Why?
| | Rats | 282 | 2024 | 5648 | 5.790 |
Why?
| | Morphine | 41 | 2020 | 158 | 5.730 |
Why?
| | Neuroglia | 39 | 2015 | 173 | 4.830 |
Why?
| | Analgesics, Opioid | 38 | 2019 | 1002 | 4.090 |
Why?
| | Interleukin-10 | 23 | 2024 | 302 | 4.000 |
Why?
| | Neuroimmunomodulation | 34 | 2024 | 65 | 3.680 |
Why?
| | Animals | 363 | 2024 | 36951 | 3.300 |
Why?
| | Cytokines | 53 | 2024 | 2085 | 3.210 |
Why?
| | Interleukin-1beta | 33 | 2023 | 372 | 3.010 |
Why?
| | Interleukin-1 | 51 | 2011 | 965 | 2.920 |
Why?
| | Spinal Cord Injuries | 9 | 2021 | 212 | 2.900 |
Why?
| | Stress, Psychological | 60 | 2020 | 1108 | 2.850 |
Why?
| | Inflammation | 51 | 2024 | 2838 | 2.670 |
Why?
| | Sciatic Neuropathy | 13 | 2023 | 29 | 2.570 |
Why?
| | Behavior, Animal | 55 | 2020 | 501 | 2.560 |
Why?
| | Lymphocyte Antigen 96 | 12 | 2019 | 24 | 2.500 |
Why?
| | Lipopolysaccharides | 52 | 2023 | 886 | 2.480 |
Why?
| | Genetic Therapy | 16 | 2024 | 297 | 2.380 |
Why?
| | Injections, Spinal | 39 | 2018 | 105 | 2.330 |
Why?
| | Hippocampus | 51 | 2020 | 895 | 2.310 |
Why?
| | Pain Threshold | 23 | 2019 | 74 | 2.310 |
Why?
| | Central Nervous System | 13 | 2018 | 258 | 2.300 |
Why?
| | Pain Measurement | 37 | 2024 | 524 | 2.090 |
Why?
| | Stress, Physiological | 45 | 2017 | 443 | 2.090 |
Why?
| | Narcotic Antagonists | 20 | 2020 | 181 | 2.070 |
Why?
| | Signal Transduction | 41 | 2019 | 5081 | 2.070 |
Why?
| | Inflammasomes | 9 | 2023 | 131 | 2.020 |
Why?
| | Corticosterone | 33 | 2019 | 236 | 2.020 |
Why?
| | Inflammation Mediators | 16 | 2020 | 513 | 1.850 |
Why?
| | Analgesia | 13 | 2015 | 94 | 1.850 |
Why?
| | Naltrexone | 19 | 2023 | 97 | 1.840 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 2021 | 68 | 1.810 |
Why?
| | Raphe Nuclei | 30 | 2014 | 110 | 1.780 |
Why?
| | Male | 285 | 2024 | 67906 | 1.780 |
Why?
| | Adenosine A2 Receptor Agonists | 4 | 2018 | 21 | 1.750 |
Why?
| | Chronic Pain | 7 | 2023 | 265 | 1.740 |
Why?
| | Disease Models, Animal | 46 | 2024 | 4295 | 1.700 |
Why?
| | HIV Envelope Protein gp120 | 12 | 2010 | 60 | 1.650 |
Why?
| | Vagus Nerve | 16 | 2001 | 86 | 1.580 |
Why?
| | Fear | 34 | 2020 | 340 | 1.540 |
Why?
| | Plasmids | 9 | 2024 | 363 | 1.540 |
Why?
| | Sciatic Nerve | 11 | 2024 | 58 | 1.510 |
Why?
| | Peripheral Nervous System Diseases | 10 | 2012 | 128 | 1.500 |
Why?
| | Naloxone | 16 | 2019 | 122 | 1.460 |
Why?
| | Prefrontal Cortex | 20 | 2018 | 303 | 1.440 |
Why?
| | HMGB1 Protein | 12 | 2019 | 50 | 1.410 |
Why?
| | Brain | 34 | 2024 | 2677 | 1.370 |
Why?
| | Helplessness, Learned | 21 | 2012 | 68 | 1.370 |
Why?
| | Minocycline | 8 | 2017 | 27 | 1.290 |
Why?
| | Encephalitis | 10 | 2018 | 136 | 1.280 |
Why?
| | Neurons | 26 | 2022 | 1590 | 1.230 |
Why?
| | Receptors, Interleukin-1 | 17 | 2016 | 216 | 1.210 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 11 | 2023 | 151 | 1.190 |
Why?
| | Electroshock | 61 | 2018 | 142 | 1.180 |
Why?
| | Astrocytes | 10 | 2019 | 210 | 1.180 |
Why?
| | Glucocorticoids | 17 | 2019 | 596 | 1.140 |
Why?
| | Tumor Necrosis Factor-alpha | 27 | 2019 | 1242 | 1.130 |
Why?
| | Serotonin | 32 | 2020 | 323 | 1.120 |
Why?
| | Peripheral Nerve Injuries | 5 | 2023 | 36 | 1.120 |
Why?
| | Conditioning, Classical | 11 | 2020 | 103 | 1.120 |
Why?
| | Piperidines | 5 | 2018 | 206 | 1.120 |
Why?
| | Pain Management | 8 | 2021 | 358 | 1.120 |
Why?
| | Escape Reaction | 25 | 2014 | 62 | 1.110 |
Why?
| | Toll-Like Receptor 2 | 7 | 2021 | 115 | 1.090 |
Why?
| | Immune System | 8 | 2012 | 177 | 1.080 |
Why?
| | Nucleus Accumbens | 9 | 2019 | 138 | 1.060 |
Why?
| | Dependovirus | 2 | 2024 | 68 | 1.050 |
Why?
| | Central Nervous System Stimulants | 6 | 2019 | 161 | 1.040 |
Why?
| | Memory Disorders | 15 | 2020 | 164 | 1.010 |
Why?
| | Osteoarthritis | 2 | 2020 | 185 | 0.950 |
Why?
| | Dose-Response Relationship, Drug | 41 | 2023 | 2057 | 0.930 |
Why?
| | Escherichia coli Infections | 15 | 2014 | 111 | 0.920 |
Why?
| | Conditioning, Operant | 13 | 2017 | 100 | 0.920 |
Why?
| | Low-Level Light Therapy | 1 | 2024 | 3 | 0.910 |
Why?
| | Circadian Rhythm | 8 | 2019 | 468 | 0.890 |
Why?
| | MicroRNAs | 3 | 2021 | 692 | 0.890 |
Why?
| | RNA, Messenger | 26 | 2017 | 2834 | 0.870 |
Why?
| | Dopamine | 8 | 2019 | 304 | 0.860 |
Why?
| | Ventral Tegmental Area | 4 | 2019 | 59 | 0.860 |
Why?
| | Glucuronides | 2 | 2014 | 18 | 0.850 |
Why?
| | Vagotomy | 15 | 2001 | 33 | 0.850 |
Why?
| | Fever | 11 | 2011 | 306 | 0.850 |
Why?
| | Alarmins | 5 | 2018 | 26 | 0.850 |
Why?
| | Ganglia, Spinal | 6 | 2016 | 78 | 0.840 |
Why?
| | Psoriasis | 1 | 2024 | 102 | 0.840 |
Why?
| | Posterior Horn Cells | 2 | 2019 | 9 | 0.840 |
Why?
| | Narcotics | 8 | 2014 | 52 | 0.810 |
Why?
| | Aging | 16 | 2021 | 1865 | 0.810 |
Why?
| | Cocaine | 5 | 2023 | 166 | 0.800 |
Why?
| | Pyridines | 7 | 2017 | 506 | 0.800 |
Why?
| | Physical Stimulation | 13 | 2014 | 65 | 0.800 |
Why?
| | Motor Activity | 21 | 2023 | 718 | 0.790 |
Why?
| | Morphine Derivatives | 2 | 2014 | 17 | 0.780 |
Why?
| | Toll-Like Receptors | 6 | 2017 | 185 | 0.770 |
Why?
| | Analysis of Variance | 27 | 2018 | 1316 | 0.770 |
Why?
| | Chemokines, CX3C | 4 | 2005 | 10 | 0.760 |
Why?
| | Drug Delivery Systems | 5 | 2024 | 365 | 0.740 |
Why?
| | Methamphetamine | 3 | 2019 | 63 | 0.730 |
Why?
| | Time Factors | 42 | 2019 | 6834 | 0.730 |
Why?
| | Rats, Inbred F344 | 19 | 2018 | 265 | 0.720 |
Why?
| | Drug Tolerance | 6 | 2017 | 105 | 0.720 |
Why?
| | Sciatica | 6 | 2012 | 7 | 0.710 |
Why?
| | Interleukin-6 | 16 | 2014 | 778 | 0.700 |
Why?
| | Migraine Disorders | 3 | 2017 | 102 | 0.680 |
Why?
| | Phenethylamines | 2 | 2018 | 23 | 0.680 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 496 | 0.680 |
Why?
| | Amygdala | 10 | 2017 | 191 | 0.670 |
Why?
| | Pain, Intractable | 3 | 2010 | 10 | 0.670 |
Why?
| | Nociceptors | 8 | 2006 | 38 | 0.660 |
Why?
| | Anxiety | 15 | 2020 | 1043 | 0.650 |
Why?
| | Nicotinic Agonists | 2 | 2012 | 129 | 0.650 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 14 | 2012 | 253 | 0.650 |
Why?
| | Arthralgia | 1 | 2020 | 56 | 0.650 |
Why?
| | Laparotomy | 5 | 2020 | 109 | 0.620 |
Why?
| | Substance-Related Disorders | 4 | 2024 | 1083 | 0.620 |
Why?
| | Gene Expression Regulation | 19 | 2019 | 2607 | 0.610 |
Why?
| | Defecation | 1 | 2019 | 19 | 0.610 |
Why?
| | Adenosine | 2 | 2018 | 225 | 0.600 |
Why?
| | Chronobiology Disorders | 1 | 2018 | 13 | 0.600 |
Why?
| | Receptors, Nicotinic | 2 | 2012 | 334 | 0.600 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 623 | 0.600 |
Why?
| | Synapses | 1 | 2022 | 427 | 0.580 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 455 | 0.580 |
Why?
| | Spinal Cord Dorsal Horn | 3 | 2019 | 5 | 0.580 |
Why?
| | Sex Characteristics | 5 | 2018 | 763 | 0.570 |
Why?
| | Neurons, Afferent | 4 | 2007 | 97 | 0.550 |
Why?
| | Neuroprotective Agents | 3 | 2015 | 131 | 0.550 |
Why?
| | Immunity, Innate | 14 | 2019 | 828 | 0.550 |
Why?
| | Ethanol | 5 | 2014 | 608 | 0.540 |
Why?
| | Trigeminal Caudal Nucleus | 1 | 2017 | 1 | 0.540 |
Why?
| | Contusions | 1 | 2017 | 20 | 0.540 |
Why?
| | Proto-Oncogene Proteins c-fos | 14 | 2018 | 185 | 0.530 |
Why?
| | Facial Nerve Injuries | 1 | 2016 | 3 | 0.530 |
Why?
| | Humans | 93 | 2024 | 137782 | 0.530 |
Why?
| | Macrophages | 11 | 2017 | 1549 | 0.530 |
Why?
| | Spinal Injuries | 1 | 2017 | 53 | 0.530 |
Why?
| | Reactive Nitrogen Species | 1 | 2016 | 21 | 0.520 |
Why?
| | Membrane Proteins | 5 | 2010 | 1164 | 0.520 |
Why?
| | Facial Nerve | 1 | 2016 | 38 | 0.520 |
Why?
| | Exercise Movement Techniques | 1 | 2016 | 7 | 0.520 |
Why?
| | NADPH Oxidases | 1 | 2016 | 113 | 0.500 |
Why?
| | Catheters, Indwelling | 3 | 2012 | 91 | 0.500 |
Why?
| | Reward | 8 | 2015 | 245 | 0.500 |
Why?
| | Reaction Time | 17 | 2012 | 414 | 0.500 |
Why?
| | Cells, Cultured | 17 | 2020 | 4193 | 0.500 |
Why?
| | Memory | 10 | 2018 | 248 | 0.500 |
Why?
| | Pain, Postoperative | 1 | 2019 | 267 | 0.500 |
Why?
| | DNA | 6 | 2024 | 1459 | 0.490 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 2014 | 136 | 0.490 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2018 | 220 | 0.490 |
Why?
| | Xanthines | 2 | 2014 | 19 | 0.480 |
Why?
| | Catheterization | 6 | 2007 | 179 | 0.480 |
Why?
| | Hindlimb | 3 | 2013 | 128 | 0.480 |
Why?
| | Excitatory Amino Acid Transporter 2 | 2 | 2016 | 16 | 0.470 |
Why?
| | Dorsal Raphe Nucleus | 4 | 2020 | 31 | 0.460 |
Why?
| | Microinjections | 19 | 2018 | 86 | 0.460 |
Why?
| | Liver | 6 | 2019 | 1943 | 0.460 |
Why?
| | Paralysis | 2 | 2015 | 71 | 0.450 |
Why?
| | Endotoxins | 5 | 2012 | 220 | 0.450 |
Why?
| | Xenobiotics | 1 | 2015 | 32 | 0.450 |
Why?
| | Resilience, Psychological | 3 | 2018 | 128 | 0.450 |
Why?
| | Gliosis | 4 | 2013 | 28 | 0.430 |
Why?
| | Fatigue | 1 | 2016 | 329 | 0.430 |
Why?
| | Chronic Disease | 11 | 2017 | 1794 | 0.420 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1998 | 0.420 |
Why?
| | Neuropharmacology | 1 | 2013 | 5 | 0.420 |
Why?
| | Hot Temperature | 10 | 2009 | 391 | 0.410 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 140 | 0.410 |
Why?
| | Disease | 4 | 1999 | 98 | 0.400 |
Why?
| | Corticotropin-Releasing Hormone | 7 | 2005 | 68 | 0.400 |
Why?
| | Glucuronic Acid | 1 | 2013 | 25 | 0.400 |
Why?
| | Quinuclidines | 1 | 2012 | 9 | 0.400 |
Why?
| | Allergy and Immunology | 1 | 2013 | 43 | 0.390 |
Why?
| | HSP90 Heat-Shock Proteins | 2 | 2010 | 46 | 0.390 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2014 | 99 | 0.390 |
Why?
| | Injections, Intraperitoneal | 16 | 2009 | 114 | 0.380 |
Why?
| | Models, Animal | 1 | 2014 | 384 | 0.380 |
Why?
| | Estradiol | 2 | 2014 | 521 | 0.380 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1168 | 0.380 |
Why?
| | Facial Pain | 1 | 2012 | 12 | 0.370 |
Why?
| | Thiophenes | 1 | 2012 | 117 | 0.370 |
Why?
| | Exploratory Behavior | 7 | 2018 | 92 | 0.370 |
Why?
| | Mice | 24 | 2024 | 17794 | 0.370 |
Why?
| | Neural Pathways | 12 | 2018 | 296 | 0.370 |
Why?
| | Hyperesthesia | 3 | 2007 | 6 | 0.370 |
Why?
| | Protein Kinase C | 1 | 2013 | 261 | 0.370 |
Why?
| | Neuralgia, Postherpetic | 1 | 2012 | 40 | 0.370 |
Why?
| | NF-kappa B | 8 | 2019 | 691 | 0.360 |
Why?
| | Complement System Proteins | 2 | 2005 | 327 | 0.360 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2009 | 131 | 0.360 |
Why?
| | Animals, Newborn | 14 | 2019 | 844 | 0.350 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 46 | 0.350 |
Why?
| | CD11b Antigen | 6 | 2010 | 61 | 0.350 |
Why?
| | Drug-Seeking Behavior | 2 | 2023 | 22 | 0.340 |
Why?
| | Avoidance Learning | 5 | 2018 | 76 | 0.340 |
Why?
| | Diet, High-Fat | 3 | 2017 | 247 | 0.340 |
Why?
| | Ceftriaxone | 1 | 2010 | 21 | 0.330 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2010 | 32 | 0.330 |
Why?
| | Chemokines | 3 | 2021 | 228 | 0.330 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 11 | 2012 | 976 | 0.320 |
Why?
| | Receptor, Adenosine A2A | 1 | 2009 | 20 | 0.320 |
Why?
| | Female | 35 | 2024 | 73465 | 0.320 |
Why?
| | Genetic Vectors | 4 | 2024 | 319 | 0.320 |
Why?
| | Up-Regulation | 4 | 2013 | 843 | 0.310 |
Why?
| | Morphinans | 3 | 2015 | 8 | 0.310 |
Why?
| | Self Administration | 5 | 2023 | 123 | 0.310 |
Why?
| | Receptors, Opioid, mu | 6 | 2020 | 74 | 0.310 |
Why?
| | Respiratory Insufficiency | 2 | 2014 | 318 | 0.310 |
Why?
| | Constriction, Pathologic | 4 | 2016 | 245 | 0.310 |
Why?
| | Meninges | 2 | 2006 | 43 | 0.310 |
Why?
| | Formaldehyde | 6 | 2013 | 63 | 0.310 |
Why?
| | Sialoglycoproteins | 8 | 2004 | 159 | 0.300 |
Why?
| | Endothelial Cells | 1 | 2014 | 785 | 0.300 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2012 | 853 | 0.300 |
Why?
| | Cell Line | 13 | 2019 | 2847 | 0.300 |
Why?
| | Neurotransmitter Agents | 2 | 2006 | 81 | 0.300 |
Why?
| | Behavior | 3 | 2006 | 90 | 0.300 |
Why?
| | Functional Laterality | 7 | 2016 | 223 | 0.300 |
Why?
| | Parkinson Disease | 1 | 2014 | 498 | 0.300 |
Why?
| | Wakefulness | 1 | 2009 | 125 | 0.300 |
Why?
| | Mice, Inbred BALB C | 7 | 2014 | 1272 | 0.290 |
Why?
| | Injections, Subcutaneous | 9 | 2012 | 157 | 0.290 |
Why?
| | HEK293 Cells | 6 | 2024 | 730 | 0.290 |
Why?
| | Cerebral Cortex | 4 | 2018 | 433 | 0.290 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2004 | 164 | 0.290 |
Why?
| | Glutamic Acid | 1 | 2010 | 246 | 0.290 |
Why?
| | Face | 1 | 2009 | 173 | 0.280 |
Why?
| | Molecular Dynamics Simulation | 3 | 2019 | 213 | 0.280 |
Why?
| | Receptors, Opioid | 3 | 2011 | 25 | 0.280 |
Why?
| | Microdialysis | 13 | 2012 | 52 | 0.280 |
Why?
| | Receptors, Immunologic | 3 | 2019 | 216 | 0.280 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2011 | 179 | 0.280 |
Why?
| | Transgenes | 2 | 2024 | 180 | 0.280 |
Why?
| | Receptors, Complement | 2 | 2005 | 122 | 0.280 |
Why?
| | Drug Design | 2 | 2010 | 167 | 0.270 |
Why?
| | Cues | 8 | 2013 | 314 | 0.270 |
Why?
| | Biomedical Research | 2 | 2013 | 700 | 0.270 |
Why?
| | Constriction | 3 | 2023 | 47 | 0.270 |
Why?
| | Clozapine | 2 | 2018 | 20 | 0.270 |
Why?
| | Hypothalamus | 5 | 2008 | 153 | 0.270 |
Why?
| | Alkaline Phosphatase | 3 | 2014 | 148 | 0.270 |
Why?
| | Crotalid Venoms | 2 | 2004 | 31 | 0.270 |
Why?
| | Locomotion | 2 | 2018 | 106 | 0.270 |
Why?
| | Phospholipases A | 2 | 2004 | 102 | 0.270 |
Why?
| | Drug Administration Schedule | 7 | 2019 | 786 | 0.260 |
Why?
| | Cognition | 6 | 2018 | 1157 | 0.260 |
Why?
| | Mycobacterium | 2 | 2018 | 108 | 0.260 |
Why?
| | Chemokine CX3CL1 | 5 | 2008 | 24 | 0.260 |
Why?
| | Nitric Oxide | 7 | 2019 | 915 | 0.260 |
Why?
| | Immunocompetence | 1 | 2006 | 42 | 0.260 |
Why?
| | Nerve Tissue Proteins | 5 | 2011 | 596 | 0.250 |
Why?
| | Limbic System | 3 | 2019 | 47 | 0.250 |
Why?
| | Transfection | 3 | 2018 | 945 | 0.250 |
Why?
| | Ketamine | 3 | 2018 | 94 | 0.250 |
Why?
| | Dinoprostone | 4 | 2014 | 191 | 0.250 |
Why?
| | Corpus Striatum | 3 | 2018 | 168 | 0.250 |
Why?
| | Immunohistochemistry | 17 | 2010 | 1738 | 0.250 |
Why?
| | Citrates | 6 | 2006 | 44 | 0.250 |
Why?
| | Neuronal Plasticity | 3 | 2022 | 290 | 0.240 |
Why?
| | Extinction, Psychological | 5 | 2023 | 86 | 0.240 |
Why?
| | Cisterna Magna | 4 | 2013 | 8 | 0.240 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2012 | 197 | 0.240 |
Why?
| | Adaptation, Psychological | 2 | 2010 | 662 | 0.240 |
Why?
| | Freezing Reaction, Cataleptic | 4 | 2013 | 22 | 0.240 |
Why?
| | Paclitaxel | 1 | 2006 | 230 | 0.240 |
Why?
| | Oxycodone | 3 | 2019 | 42 | 0.240 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2006 | 191 | 0.240 |
Why?
| | Bacterial Infections | 4 | 2009 | 250 | 0.230 |
Why?
| | Protein Binding | 9 | 2018 | 2224 | 0.230 |
Why?
| | DNA-Binding Proteins | 3 | 2023 | 1502 | 0.230 |
Why?
| | Arousal | 6 | 2002 | 155 | 0.230 |
Why?
| | Aminoquinolines | 1 | 2024 | 19 | 0.230 |
Why?
| | Antibodies | 6 | 2018 | 410 | 0.230 |
Why?
| | Analgesics | 5 | 2020 | 206 | 0.230 |
Why?
| | Spinal Nerve Roots | 3 | 2012 | 29 | 0.230 |
Why?
| | Infrared Rays | 1 | 2024 | 25 | 0.220 |
Why?
| | Models, Immunological | 1 | 2005 | 100 | 0.220 |
Why?
| | Cyclooxygenase 2 | 4 | 2019 | 178 | 0.220 |
Why?
| | Ligation | 3 | 2013 | 92 | 0.220 |
Why?
| | Brain Mapping | 8 | 2018 | 503 | 0.220 |
Why?
| | Nitric Oxide Synthase | 2 | 2004 | 240 | 0.220 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 130 | 0.220 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 351 | 0.220 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2008 | 87 | 0.220 |
Why?
| | Injections, Intraventricular | 13 | 2015 | 55 | 0.220 |
Why?
| | Vesiculovirus | 1 | 2024 | 16 | 0.220 |
Why?
| | Models, Neurological | 2 | 2003 | 242 | 0.220 |
Why?
| | Central Nervous System Agents | 1 | 2003 | 5 | 0.220 |
Why?
| | Gap Junctions | 1 | 2004 | 59 | 0.210 |
Why?
| | Body Fluids | 1 | 2004 | 66 | 0.210 |
Why?
| | Cholecystokinin | 4 | 2000 | 12 | 0.210 |
Why?
| | Glial Fibrillary Acidic Protein | 8 | 2015 | 100 | 0.210 |
Why?
| | Transduction, Genetic | 1 | 2024 | 127 | 0.210 |
Why?
| | Neural Inhibition | 2 | 2010 | 169 | 0.210 |
Why?
| | Lumbosacral Region | 4 | 2013 | 59 | 0.210 |
Why?
| | Norepinephrine | 5 | 2005 | 204 | 0.210 |
Why?
| | Central Nervous System Diseases | 2 | 2017 | 69 | 0.210 |
Why?
| | Antigens, CD | 4 | 2017 | 521 | 0.210 |
Why?
| | Carrier Proteins | 5 | 2015 | 771 | 0.200 |
Why?
| | Mice, Knockout | 5 | 2021 | 3018 | 0.200 |
Why?
| | Animals, Genetically Modified | 1 | 2024 | 240 | 0.200 |
Why?
| | Learning | 7 | 2018 | 409 | 0.200 |
Why?
| | Adrenalectomy | 10 | 2014 | 68 | 0.200 |
Why?
| | Enzyme Inhibitors | 6 | 2007 | 840 | 0.200 |
Why?
| | Mifepristone | 6 | 2019 | 64 | 0.200 |
Why?
| | Opioid-Related Disorders | 5 | 2017 | 515 | 0.200 |
Why?
| | Pituitary Gland | 6 | 2004 | 148 | 0.200 |
Why?
| | Freund's Adjuvant | 2 | 2013 | 18 | 0.200 |
Why?
| | Receptors, Glucocorticoid | 5 | 2016 | 155 | 0.200 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 383 | 0.190 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 220 | 0.190 |
Why?
| | Illness Behavior | 2 | 2014 | 9 | 0.190 |
Why?
| | Brain Chemistry | 3 | 2004 | 117 | 0.190 |
Why?
| | Fibroblast Growth Factor 2 | 3 | 2007 | 87 | 0.190 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2021 | 51 | 0.190 |
Why?
| | Gene Expression | 8 | 2020 | 1502 | 0.190 |
Why?
| | Random Allocation | 6 | 2016 | 353 | 0.190 |
Why?
| | Cocaine-Related Disorders | 1 | 2023 | 113 | 0.190 |
Why?
| | Indoles | 4 | 2013 | 412 | 0.190 |
Why?
| | Synaptic Transmission | 4 | 2010 | 289 | 0.190 |
Why?
| | Caspase 1 | 3 | 2020 | 144 | 0.190 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 283 | 0.190 |
Why?
| | Spleen | 7 | 2014 | 514 | 0.180 |
Why?
| | Social Behavior | 8 | 2018 | 287 | 0.180 |
Why?
| | Affect | 3 | 2018 | 292 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 411 | 0.180 |
Why?
| | Psychoneuroimmunology | 3 | 2002 | 10 | 0.180 |
Why?
| | Immunity, Cellular | 2 | 2002 | 268 | 0.180 |
Why?
| | GABA Antagonists | 4 | 2010 | 35 | 0.180 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2012 | 97 | 0.180 |
Why?
| | Tail | 11 | 2007 | 28 | 0.170 |
Why?
| | Fentanyl | 2 | 2019 | 94 | 0.170 |
Why?
| | Central Nervous System Depressants | 2 | 2014 | 85 | 0.170 |
Why?
| | Zymosan | 4 | 2005 | 65 | 0.170 |
Why?
| | Cell Communication | 3 | 2009 | 315 | 0.170 |
Why?
| | 8-Hydroxy-2-(di-n-propylamino)tetralin | 4 | 2009 | 8 | 0.170 |
Why?
| | Body Temperature | 5 | 2002 | 222 | 0.170 |
Why?
| | Receptors, HIV | 3 | 2004 | 24 | 0.170 |
Why?
| | Neurogenesis | 1 | 2022 | 149 | 0.170 |
Why?
| | Touch | 3 | 2013 | 36 | 0.170 |
Why?
| | Dexamethasone | 5 | 2012 | 370 | 0.170 |
Why?
| | Receptors, Cytokine | 3 | 2004 | 36 | 0.170 |
Why?
| | Drug Interactions | 6 | 2008 | 410 | 0.170 |
Why?
| | Models, Molecular | 5 | 2012 | 1570 | 0.170 |
Why?
| | Thoracic Vertebrae | 2 | 2019 | 77 | 0.170 |
Why?
| | Convulsants | 4 | 1998 | 8 | 0.160 |
Why?
| | Specific Pathogen-Free Organisms | 5 | 2004 | 60 | 0.160 |
Why?
| | AIDS Dementia Complex | 1 | 2000 | 51 | 0.160 |
Why?
| | Dogs | 2 | 2020 | 413 | 0.160 |
Why?
| | Drug Synergism | 4 | 2015 | 382 | 0.160 |
Why?
| | Carbolines | 4 | 1998 | 32 | 0.160 |
Why?
| | Lithium Chloride | 3 | 1994 | 12 | 0.160 |
Why?
| | Skin | 1 | 2024 | 752 | 0.160 |
Why?
| | Lovastatin | 1 | 2019 | 37 | 0.160 |
Why?
| | Thalamus | 2 | 2018 | 107 | 0.160 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 4 | 2004 | 29 | 0.150 |
Why?
| | Hemocyanins | 8 | 2003 | 62 | 0.150 |
Why?
| | Microfilament Proteins | 3 | 2016 | 133 | 0.150 |
Why?
| | Antibody Formation | 6 | 2002 | 298 | 0.150 |
Why?
| | Diaphragm | 5 | 2001 | 42 | 0.150 |
Why?
| | CLOCK Proteins | 1 | 2018 | 8 | 0.150 |
Why?
| | Tumor Necrosis Factor Decoy Receptors | 3 | 2004 | 8 | 0.150 |
Why?
| | Pituitary-Adrenal System | 5 | 2004 | 162 | 0.150 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2018 | 8 | 0.150 |
Why?
| | Receptors, Purinergic P1 | 1 | 2018 | 26 | 0.150 |
Why?
| | Somatosensory Cortex | 2 | 2009 | 35 | 0.150 |
Why?
| | Motor Disorders | 1 | 2018 | 15 | 0.150 |
Why?
| | Immunization | 4 | 2018 | 411 | 0.150 |
Why?
| | Calcium-Binding Proteins | 3 | 2016 | 218 | 0.150 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5764 | 0.150 |
Why?
| | Medulla Oblongata | 2 | 2014 | 35 | 0.150 |
Why?
| | Restraint, Physical | 11 | 2007 | 72 | 0.150 |
Why?
| | Receptor, Serotonin, 5-HT1A | 2 | 2011 | 38 | 0.150 |
Why?
| | Abdomen | 1 | 1999 | 125 | 0.140 |
Why?
| | Recombinant Proteins | 8 | 2005 | 1356 | 0.140 |
Why?
| | Maze Learning | 2 | 2016 | 103 | 0.140 |
Why?
| | Designer Drugs | 1 | 2018 | 8 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 327 | 0.140 |
Why?
| | Molecular Docking Simulation | 2 | 2018 | 114 | 0.140 |
Why?
| | Septal Nuclei | 2 | 2011 | 23 | 0.140 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2018 | 50 | 0.140 |
Why?
| | Bacterial Vaccines | 1 | 2018 | 63 | 0.140 |
Why?
| | Body Weight | 4 | 2018 | 985 | 0.140 |
Why?
| | Probiotics | 1 | 2018 | 54 | 0.140 |
Why?
| | Methadone | 2 | 2010 | 101 | 0.140 |
Why?
| | Transcortin | 4 | 1999 | 16 | 0.140 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 27 | 0.140 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 431 | 0.140 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 100 | 0.140 |
Why?
| | Muscimol | 7 | 2011 | 16 | 0.140 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2017 | 13 | 0.140 |
Why?
| | Brain Injuries | 2 | 2013 | 494 | 0.140 |
Why?
| | Amphetamine | 3 | 2010 | 35 | 0.140 |
Why?
| | Nitrites | 2 | 2016 | 84 | 0.140 |
Why?
| | Acoustic Stimulation | 5 | 2011 | 312 | 0.130 |
Why?
| | Biomarkers | 5 | 2012 | 4154 | 0.130 |
Why?
| | Taste | 3 | 2008 | 229 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 455 | 0.130 |
Why?
| | Facial Nucleus | 1 | 2016 | 1 | 0.130 |
Why?
| | Rats, Inbred Strains | 7 | 2017 | 362 | 0.130 |
Why?
| | Toll-Like Receptor 5 | 1 | 2016 | 14 | 0.130 |
Why?
| | Receptors, Purinergic P2X5 | 1 | 2016 | 4 | 0.130 |
Why?
| | Dura Mater | 1 | 2017 | 34 | 0.130 |
Why?
| | Activating Transcription Factor 3 | 1 | 2016 | 5 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2018 | 201 | 0.130 |
Why?
| | Habenula | 1 | 2016 | 13 | 0.130 |
Why?
| | Spatial Memory | 1 | 2016 | 26 | 0.130 |
Why?
| | p21-Activated Kinases | 1 | 2016 | 15 | 0.130 |
Why?
| | Models, Biological | 3 | 2017 | 1783 | 0.130 |
Why?
| | CX3C Chemokine Receptor 1 | 3 | 2004 | 19 | 0.130 |
Why?
| | Down-Regulation | 2 | 2017 | 657 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 2 | 2018 | 333 | 0.130 |
Why?
| | Radiculopathy | 2 | 2014 | 35 | 0.130 |
Why?
| | Brain Ischemia | 2 | 2018 | 338 | 0.130 |
Why?
| | Neurogenic Inflammation | 1 | 2016 | 2 | 0.120 |
Why?
| | Hydrazones | 3 | 2003 | 25 | 0.120 |
Why?
| | Cell Count | 9 | 2009 | 324 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 1997 | 125 | 0.120 |
Why?
| | Flumazenil | 1 | 1995 | 8 | 0.120 |
Why?
| | Life Expectancy | 1 | 2016 | 69 | 0.120 |
Why?
| | Nociception | 2 | 2015 | 16 | 0.120 |
Why?
| | Isomerism | 2 | 2018 | 56 | 0.120 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 286 | 0.120 |
Why?
| | Autoimmunity | 1 | 2021 | 908 | 0.120 |
Why?
| | Physical Conditioning, Animal | 3 | 2014 | 258 | 0.120 |
Why?
| | Reflex, Abnormal | 1 | 2014 | 7 | 0.120 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.120 |
Why?
| | NG-Nitroarginine Methyl Ester | 2 | 2005 | 48 | 0.110 |
Why?
| | Picrotoxin | 5 | 2018 | 12 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2010 | 641 | 0.110 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2015 | 58 | 0.110 |
Why?
| | Drug Administration Routes | 2 | 2012 | 38 | 0.110 |
Why?
| | Body Temperature Regulation | 2 | 2009 | 97 | 0.110 |
Why?
| | Mice, Inbred C3H | 1 | 2015 | 269 | 0.110 |
Why?
| | Neuropeptides | 1 | 1994 | 73 | 0.110 |
Why?
| | Circadian Clocks | 1 | 2014 | 50 | 0.110 |
Why?
| | Morphine Dependence | 2 | 2011 | 3 | 0.110 |
Why?
| | Memory, Long-Term | 3 | 2020 | 12 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2015 | 137 | 0.110 |
Why?
| | Receptors, GABA-A | 1 | 1995 | 142 | 0.110 |
Why?
| | PPAR gamma | 1 | 2015 | 182 | 0.110 |
Why?
| | Host-Pathogen Interactions | 3 | 2012 | 364 | 0.110 |
Why?
| | Nervous System | 1 | 1994 | 67 | 0.110 |
Why?
| | Brain Stem | 2 | 2010 | 94 | 0.100 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 89 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 558 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 894 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1020 | 0.100 |
Why?
| | Phosphorylation | 3 | 2012 | 1759 | 0.100 |
Why?
| | Escherichia coli | 5 | 2016 | 815 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 374 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2012 | 847 | 0.100 |
Why?
| | Recovery of Function | 1 | 2017 | 653 | 0.100 |
Why?
| | Running | 2 | 2017 | 230 | 0.100 |
Why?
| | Pentamidine | 1 | 2012 | 3 | 0.100 |
Why?
| | Blood-Brain Barrier | 2 | 2009 | 138 | 0.100 |
Why?
| | Interleukins | 2 | 2006 | 250 | 0.100 |
Why?
| | Viral Matrix Proteins | 1 | 2012 | 30 | 0.100 |
Why?
| | Swimming | 1 | 2013 | 51 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2016 | 398 | 0.100 |
Why?
| | Heroin | 1 | 2013 | 31 | 0.100 |
Why?
| | Rifampin | 1 | 2013 | 84 | 0.100 |
Why?
| | Rats, Wistar | 4 | 2016 | 455 | 0.100 |
Why?
| | Serotonin Receptor Agonists | 4 | 2013 | 26 | 0.100 |
Why?
| | Adrenocorticotropic Hormone | 6 | 2004 | 143 | 0.100 |
Why?
| | Oncogene Proteins v-fos | 4 | 2015 | 11 | 0.100 |
Why?
| | Receptors, Cholecystokinin | 1 | 1992 | 8 | 0.100 |
Why?
| | Lipopeptides | 1 | 2012 | 13 | 0.100 |
Why?
| | Organ Culture Techniques | 2 | 2010 | 156 | 0.100 |
Why?
| | Somatostatin | 1 | 1992 | 61 | 0.100 |
Why?
| | Cytoskeletal Proteins | 2 | 2010 | 158 | 0.100 |
Why?
| | Cerebral Ventricles | 1 | 1992 | 52 | 0.090 |
Why?
| | Structure-Activity Relationship | 3 | 2019 | 570 | 0.090 |
Why?
| | DNA, Complementary | 2 | 2010 | 272 | 0.090 |
Why?
| | Association Learning | 4 | 2007 | 61 | 0.090 |
Why?
| | Tetracyclines | 1 | 2012 | 11 | 0.090 |
Why?
| | Behavior, Addictive | 1 | 2013 | 81 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 145 | 0.090 |
Why?
| | Pyrazoles | 1 | 1995 | 424 | 0.090 |
Why?
| | Antigens | 3 | 2003 | 357 | 0.090 |
Why?
| | Gene Transfer Techniques | 2 | 2010 | 171 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2016 | 332 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2012 | 85 | 0.090 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 166 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 185 | 0.090 |
Why?
| | DNA Primers | 2 | 2010 | 515 | 0.090 |
Why?
| | Phenylurea Compounds | 1 | 1992 | 97 | 0.090 |
Why?
| | Mice, Inbred CBA | 1 | 2011 | 54 | 0.090 |
Why?
| | Macrophages, Peritoneal | 1 | 2011 | 94 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 430 | 0.090 |
Why?
| | Stroke | 2 | 2018 | 1120 | 0.090 |
Why?
| | Sensation | 1 | 1991 | 53 | 0.090 |
Why?
| | Heart Arrest | 1 | 2015 | 339 | 0.090 |
Why?
| | Superoxides | 2 | 2022 | 202 | 0.090 |
Why?
| | Vasodilation | 1 | 2014 | 499 | 0.090 |
Why?
| | Peptide Fragments | 3 | 2011 | 706 | 0.090 |
Why?
| | Rats, Inbred BN | 4 | 2012 | 58 | 0.090 |
Why?
| | Endocrine Glands | 1 | 1990 | 15 | 0.090 |
Why?
| | Phenylephrine | 1 | 1990 | 75 | 0.080 |
Why?
| | GABA Agonists | 4 | 2008 | 19 | 0.080 |
Why?
| | Drug Combinations | 2 | 2009 | 343 | 0.080 |
Why?
| | Benzylidene Compounds | 1 | 2010 | 20 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 644 | 0.080 |
Why?
| | Muscles | 1 | 1991 | 326 | 0.080 |
Why?
| | Sphingolipids | 1 | 2010 | 77 | 0.080 |
Why?
| | Prostaglandins | 2 | 2007 | 97 | 0.080 |
Why?
| | Food Preferences | 2 | 2008 | 120 | 0.080 |
Why?
| | Mitochondria | 1 | 2016 | 948 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 236 | 0.080 |
Why?
| | Receptor, Serotonin, 5-HT2C | 1 | 2009 | 15 | 0.080 |
Why?
| | Protein Interaction Mapping | 1 | 2010 | 109 | 0.080 |
Why?
| | Receptors, Interleukin-1 Type I | 2 | 2011 | 23 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2012 | 200 | 0.080 |
Why?
| | Stress Disorders, Traumatic | 1 | 2009 | 22 | 0.080 |
Why?
| | Bradykinin | 1 | 2009 | 46 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 256 | 0.080 |
Why?
| | Dimethyl Sulfoxide | 1 | 2009 | 41 | 0.080 |
Why?
| | Histamine | 1 | 2009 | 67 | 0.080 |
Why?
| | Afferent Pathways | 3 | 2005 | 45 | 0.080 |
Why?
| | Motor Neurons | 1 | 2012 | 234 | 0.080 |
Why?
| | Infusion Pumps | 1 | 2009 | 32 | 0.080 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 61 | 0.080 |
Why?
| | Perception | 1 | 1992 | 359 | 0.080 |
Why?
| | Toll-Like Receptor 9 | 1 | 2009 | 32 | 0.080 |
Why?
| | Amnesia, Retrograde | 2 | 2006 | 3 | 0.080 |
Why?
| | Eating | 3 | 2000 | 380 | 0.080 |
Why?
| | Injections, Intravenous | 3 | 1998 | 206 | 0.080 |
Why?
| | Lactams, Macrocyclic | 1 | 2009 | 49 | 0.080 |
Why?
| | Benzoquinones | 1 | 2009 | 48 | 0.080 |
Why?
| | Immunoglobulin M | 4 | 2001 | 289 | 0.080 |
Why?
| | Central Nervous System Infections | 1 | 2009 | 35 | 0.080 |
Why?
| | Neoplasms | 2 | 2010 | 2673 | 0.080 |
Why?
| | CpG Islands | 1 | 2009 | 157 | 0.080 |
Why?
| | Disease Susceptibility | 1 | 2011 | 347 | 0.070 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 158 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 377 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2012 | 496 | 0.070 |
Why?
| | Spatial Behavior | 1 | 2008 | 26 | 0.070 |
Why?
| | Age Factors | 7 | 2010 | 3305 | 0.070 |
Why?
| | RAW 264.7 Cells | 2 | 2019 | 50 | 0.070 |
Why?
| | Sex Factors | 2 | 2012 | 2077 | 0.070 |
Why?
| | Ligands | 1 | 2010 | 664 | 0.070 |
Why?
| | beta-Adrenergic Receptor Kinases | 1 | 2007 | 6 | 0.070 |
Why?
| | RNA, Antisense | 1 | 2007 | 17 | 0.070 |
Why?
| | Safety | 3 | 2008 | 338 | 0.070 |
Why?
| | Drugs, Investigational | 1 | 2007 | 33 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2009 | 363 | 0.070 |
Why?
| | Mental Disorders | 1 | 2016 | 1077 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2167 | 0.070 |
Why?
| | Foreign-Body Reaction | 1 | 2007 | 31 | 0.060 |
Why?
| | Cholesterol | 2 | 2003 | 410 | 0.060 |
Why?
| | GABA-A Receptor Agonists | 3 | 2011 | 16 | 0.060 |
Why?
| | Receptors, Serotonin | 2 | 1997 | 34 | 0.060 |
Why?
| | Stereoisomerism | 2 | 2019 | 96 | 0.060 |
Why?
| | Mutation | 2 | 2015 | 3959 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2006 | 129 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2013 | 1317 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 74 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2005 | 810 | 0.060 |
Why?
| | Transcriptome | 1 | 2012 | 972 | 0.060 |
Why?
| | Antibodies, Blocking | 1 | 2005 | 33 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 142 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1294 | 0.060 |
Why?
| | Centrifugation | 1 | 2005 | 30 | 0.060 |
Why?
| | Electric Stimulation | 4 | 2011 | 264 | 0.060 |
Why?
| | Peptides | 2 | 2009 | 985 | 0.060 |
Why?
| | Histocompatibility Antigens | 1 | 2006 | 105 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2012 | 2659 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 81 | 0.060 |
Why?
| | Cell Survival | 3 | 2019 | 1120 | 0.060 |
Why?
| | Reinforcement Schedule | 3 | 2017 | 31 | 0.060 |
Why?
| | Blotting, Western | 3 | 2013 | 1227 | 0.060 |
Why?
| | Epilepsy | 1 | 2009 | 333 | 0.060 |
Why?
| | Adrenal Glands | 2 | 2018 | 78 | 0.060 |
Why?
| | Complement C5a | 1 | 2005 | 71 | 0.060 |
Why?
| | Hormone Antagonists | 3 | 2016 | 34 | 0.060 |
Why?
| | Complement C3a | 1 | 2005 | 42 | 0.060 |
Why?
| | Electric Countershock | 2 | 1984 | 107 | 0.060 |
Why?
| | Carbenoxolone | 1 | 2004 | 1 | 0.060 |
Why?
| | Glycyrrhizic Acid | 1 | 2004 | 3 | 0.060 |
Why?
| | Computer Simulation | 1 | 2009 | 982 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2007 | 485 | 0.060 |
Why?
| | Anti-Ulcer Agents | 1 | 2004 | 16 | 0.060 |
Why?
| | Nerve Compression Syndromes | 1 | 2004 | 21 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1092 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1052 | 0.060 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2004 | 28 | 0.060 |
Why?
| | Hypothermia | 1 | 2004 | 36 | 0.050 |
Why?
| | Cell Separation | 1 | 2005 | 318 | 0.050 |
Why?
| | Adenoviridae | 1 | 2005 | 193 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2004 | 45 | 0.050 |
Why?
| | N-Methylaspartate | 1 | 2004 | 40 | 0.050 |
Why?
| | Catalase | 1 | 2004 | 130 | 0.050 |
Why?
| | Binding Sites | 2 | 2018 | 1303 | 0.050 |
Why?
| | Receptors, Opioid, kappa | 2 | 1994 | 10 | 0.050 |
Why?
| | Peripheral Nervous System | 1 | 2003 | 20 | 0.050 |
Why?
| | Sample Size | 1 | 2004 | 125 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 1 | 2023 | 39 | 0.050 |
Why?
| | Hydrocortisone | 5 | 2009 | 322 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2010 | 367 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2024 | 84 | 0.050 |
Why?
| | Mental Recall | 2 | 1995 | 204 | 0.050 |
Why?
| | Lymph Nodes | 3 | 2001 | 491 | 0.050 |
Why?
| | Aconitate Hydratase | 1 | 2003 | 17 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2009 | 597 | 0.050 |
Why?
| | Adult | 4 | 2022 | 38023 | 0.050 |
Why?
| | Pressure | 1 | 2004 | 225 | 0.050 |
Why?
| | Immunoglobulin G | 4 | 2002 | 893 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 363 | 0.050 |
Why?
| | Neck | 2 | 2001 | 101 | 0.050 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2002 | 17 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2002 | 36 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2003 | 65 | 0.050 |
Why?
| | Immobility Response, Tonic | 2 | 2013 | 5 | 0.050 |
Why?
| | Reflex | 2 | 1994 | 68 | 0.050 |
Why?
| | Social Isolation | 1 | 2003 | 62 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 385 | 0.050 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 13 | 0.050 |
Why?
| | Glycoproteins | 1 | 2024 | 342 | 0.050 |
Why?
| | Psychomotor Performance | 3 | 2015 | 309 | 0.050 |
Why?
| | NADPH Oxidase 2 | 1 | 2022 | 39 | 0.050 |
Why?
| | Antioxidants | 2 | 2022 | 585 | 0.050 |
Why?
| | Death, Sudden | 1 | 1982 | 24 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 346 | 0.050 |
Why?
| | Nodose Ganglion | 2 | 1998 | 6 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2004 | 246 | 0.050 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 146 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2023 | 167 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 346 | 0.050 |
Why?
| | Evoked Potentials, Auditory | 2 | 2011 | 180 | 0.050 |
Why?
| | Stem Cells | 1 | 2006 | 594 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3415 | 0.050 |
Why?
| | Ventricular Fibrillation | 1 | 1982 | 60 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 2 | 1995 | 417 | 0.050 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2022 | 173 | 0.050 |
Why?
| | Viral Proteins | 1 | 2024 | 342 | 0.050 |
Why?
| | Interferon-gamma | 4 | 2001 | 789 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 500 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 313 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3290 | 0.040 |
Why?
| | Acute Disease | 2 | 2001 | 1007 | 0.040 |
Why?
| | Epinephrine | 3 | 2002 | 141 | 0.040 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 93 | 0.040 |
Why?
| | Protein Conformation | 2 | 2018 | 934 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 345 | 0.040 |
Why?
| | Injections | 2 | 2013 | 183 | 0.040 |
Why?
| | Aminopyridines | 2 | 2013 | 98 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2020 | 6 | 0.040 |
Why?
| | Organ Size | 1 | 2001 | 477 | 0.040 |
Why?
| | Depression | 2 | 2008 | 1408 | 0.040 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2011 | 33 | 0.040 |
Why?
| | Rodentia | 1 | 2020 | 57 | 0.040 |
Why?
| | Crisis Intervention | 1 | 2020 | 33 | 0.040 |
Why?
| | Alzheimer Disease | 2 | 2020 | 560 | 0.040 |
Why?
| | Adjuvants, Immunologic | 2 | 2003 | 226 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2139 | 0.040 |
Why?
| | Receptors, Mineralocorticoid | 1 | 1999 | 10 | 0.040 |
Why?
| | Peritoneum | 1 | 2000 | 44 | 0.040 |
Why?
| | Subarachnoid Space | 1 | 1999 | 8 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 77 | 0.040 |
Why?
| | Urocortins | 3 | 2004 | 23 | 0.040 |
Why?
| | Paresis | 1 | 1999 | 30 | 0.040 |
Why?
| | Pyrimidines | 2 | 2003 | 471 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Fluorescent Dyes | 2 | 2012 | 321 | 0.040 |
Why?
| | Coronary Disease | 1 | 1982 | 385 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 1999 | 28 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1946 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1809 | 0.040 |
Why?
| | alpha-MSH | 1 | 1998 | 5 | 0.040 |
Why?
| | Immunity | 1 | 2000 | 143 | 0.040 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 57 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Acute-Phase Reaction | 1 | 1998 | 41 | 0.040 |
Why?
| | Cerebellum | 1 | 2000 | 224 | 0.040 |
Why?
| | Glossopharyngeal Nerve | 1 | 1998 | 11 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2001 | 69 | 0.040 |
Why?
| | Optical Fibers | 1 | 2018 | 17 | 0.040 |
Why?
| | Limbic Lobe | 1 | 2018 | 3 | 0.040 |
Why?
| | Neuroanatomical Tract-Tracing Techniques | 1 | 2018 | 5 | 0.040 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2005 | 605 | 0.040 |
Why?
| | Stilbamidines | 1 | 2018 | 10 | 0.040 |
Why?
| | Injections, Epidural | 1 | 1998 | 26 | 0.040 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 68 | 0.040 |
Why?
| | Protein Structure, Secondary | 1 | 2019 | 374 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 390 | 0.040 |
Why?
| | Bromodeoxyuridine | 2 | 2009 | 79 | 0.040 |
Why?
| | Administration, Intranasal | 1 | 2018 | 90 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2020 | 252 | 0.040 |
Why?
| | Cell Proliferation | 3 | 2012 | 2475 | 0.030 |
Why?
| | Isonicotinic Acids | 1 | 1997 | 2 | 0.030 |
Why?
| | Receptors, GABA | 1 | 1997 | 14 | 0.030 |
Why?
| | Thermosensing | 2 | 1997 | 12 | 0.030 |
Why?
| | Sucrose | 2 | 2008 | 110 | 0.030 |
Why?
| | Pyrroles | 1 | 1999 | 213 | 0.030 |
Why?
| | Oxytocics | 1 | 1997 | 15 | 0.030 |
Why?
| | Amnesia, Anterograde | 2 | 2008 | 4 | 0.030 |
Why?
| | Immunoassay | 1 | 2018 | 115 | 0.030 |
Why?
| | Biguanides | 1 | 1997 | 12 | 0.030 |
Why?
| | Baclofen | 1 | 1997 | 19 | 0.030 |
Why?
| | Mannose | 1 | 2017 | 24 | 0.030 |
Why?
| | Analgesia, Epidural | 1 | 1997 | 33 | 0.030 |
Why?
| | Histocytochemistry | 1 | 1997 | 80 | 0.030 |
Why?
| | Skin Temperature | 2 | 1994 | 30 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 2 | 2007 | 26 | 0.030 |
Why?
| | Basolateral Nuclear Complex | 1 | 2016 | 11 | 0.030 |
Why?
| | Nerve Net | 1 | 2000 | 256 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 622 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 184 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1999 | 378 | 0.030 |
Why?
| | Extracellular Space | 2 | 2009 | 119 | 0.030 |
Why?
| | Period Circadian Proteins | 1 | 2016 | 16 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2016 | 134 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1996 | 171 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 127 | 0.030 |
Why?
| | Psychological Tests | 1 | 2016 | 140 | 0.030 |
Why?
| | Anesthetics, Dissociative | 1 | 2016 | 30 | 0.030 |
Why?
| | Dentate Gyrus | 2 | 2006 | 37 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1996 | 106 | 0.030 |
Why?
| | Dysgammaglobulinemia | 1 | 1995 | 2 | 0.030 |
Why?
| | IgG Deficiency | 1 | 1995 | 7 | 0.030 |
Why?
| | Leukocytes | 2 | 2011 | 311 | 0.030 |
Why?
| | Saccharin | 1 | 1995 | 6 | 0.030 |
Why?
| | Animal Diseases | 1 | 2015 | 6 | 0.030 |
Why?
| | Optogenetics | 1 | 2016 | 108 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 1995 | 87 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1995 | 50 | 0.030 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2014 | 9 | 0.030 |
Why?
| | Capsaicin | 1 | 2015 | 26 | 0.030 |
Why?
| | 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1994 | 6 | 0.030 |
Why?
| | Chlorisondamine | 1 | 1994 | 3 | 0.030 |
Why?
| | Adrenal Medulla | 1 | 1994 | 9 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 519 | 0.030 |
Why?
| | Blood Proteins | 1 | 1997 | 252 | 0.030 |
Why?
| | CD4 Antigens | 1 | 1995 | 141 | 0.030 |
Why?
| | Substance P | 1 | 1994 | 36 | 0.030 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2014 | 12 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 1999 | 400 | 0.030 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 283 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2005 | 316 | 0.030 |
Why?
| | Ganglionectomy | 1 | 1994 | 2 | 0.030 |
Why?
| | Decerebrate State | 1 | 1994 | 3 | 0.030 |
Why?
| | Kupffer Cells | 1 | 1994 | 50 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 1994 | 63 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 563 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 314 | 0.030 |
Why?
| | Ganglia, Sympathetic | 1 | 1994 | 14 | 0.030 |
Why?
| | Auditory Cortex | 1 | 1994 | 42 | 0.030 |
Why?
| | Valine | 1 | 2014 | 82 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 307 | 0.030 |
Why?
| | Basal Ganglia | 1 | 1994 | 56 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 236 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2016 | 10837 | 0.030 |
Why?
| | Respiration | 1 | 2014 | 199 | 0.030 |
Why?
| | Biological Transport | 1 | 1995 | 418 | 0.030 |
Why?
| | Adiposity | 1 | 2018 | 518 | 0.030 |
Why?
| | Weight Loss | 2 | 2009 | 788 | 0.030 |
Why?
| | Pregnancy | 3 | 2017 | 6771 | 0.030 |
Why?
| | Infusion Pumps, Implantable | 1 | 2013 | 25 | 0.030 |
Why?
| | Anesthetics | 1 | 1993 | 81 | 0.020 |
Why?
| | Receptors, Opioid, delta | 1 | 1992 | 10 | 0.020 |
Why?
| | Benzodiazepinones | 1 | 1992 | 17 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2012 | 45 | 0.020 |
Why?
| | Spodoptera | 1 | 2012 | 40 | 0.020 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 219 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 29 | 0.020 |
Why?
| | Receptors, IgG | 1 | 2012 | 75 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2012 | 54 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 249 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 147 | 0.020 |
Why?
| | Gliosarcoma | 1 | 1992 | 8 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 88 | 0.020 |
Why?
| | Biological Assay | 1 | 2012 | 124 | 0.020 |
Why?
| | Lymphocyte Transfusion | 1 | 1992 | 21 | 0.020 |
Why?
| | Biophysics | 1 | 2012 | 71 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 38 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1060 | 0.020 |
Why?
| | Kinetics | 2 | 2006 | 1670 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2012 | 81 | 0.020 |
Why?
| | Dimerization | 1 | 2012 | 199 | 0.020 |
Why?
| | Foot | 1 | 1992 | 96 | 0.020 |
Why?
| | Azoles | 1 | 2011 | 4 | 0.020 |
Why?
| | Nitrobenzenes | 1 | 2011 | 13 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 134 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2011 | 39 | 0.020 |
Why?
| | Physical Exertion | 1 | 1992 | 215 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 192 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2011 | 50 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2019 | 1991 | 0.020 |
Why?
| | Molecular Mimicry | 1 | 2011 | 42 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2012 | 307 | 0.020 |
Why?
| | Biotin | 1 | 2011 | 28 | 0.020 |
Why?
| | Rotarod Performance Test | 1 | 2011 | 16 | 0.020 |
Why?
| | Reflex, Righting | 1 | 2011 | 15 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2011 | 31 | 0.020 |
Why?
| | Dextrans | 1 | 2011 | 84 | 0.020 |
Why?
| | Electrophysiology | 1 | 2011 | 217 | 0.020 |
Why?
| | Arginine Vasopressin | 1 | 1990 | 44 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 168 | 0.020 |
Why?
| | Sphingosine | 1 | 2010 | 46 | 0.020 |
Why?
| | Vasopressins | 1 | 1990 | 64 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1992 | 455 | 0.020 |
Why?
| | Lysophospholipids | 1 | 2010 | 80 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 469 | 0.020 |
Why?
| | Polyglycolic Acid | 1 | 2010 | 43 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 861 | 0.020 |
Why?
| | PC12 Cells | 1 | 2009 | 40 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 144 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2009 | 32 | 0.020 |
Why?
| | Dominance-Subordination | 1 | 2009 | 16 | 0.020 |
Why?
| | Antimetabolites | 1 | 2009 | 23 | 0.020 |
Why?
| | Genes, fos | 1 | 2009 | 36 | 0.020 |
Why?
| | Vaccination | 1 | 2018 | 1381 | 0.020 |
Why?
| | Esters | 1 | 2009 | 76 | 0.020 |
Why?
| | Drinking | 2 | 1999 | 42 | 0.020 |
Why?
| | Temperature | 1 | 1992 | 679 | 0.020 |
Why?
| | Adaptation, Physiological | 2 | 2003 | 553 | 0.020 |
Why?
| | Electromyography | 1 | 1991 | 400 | 0.020 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2008 | 7 | 0.020 |
Why?
| | Aldehydes | 1 | 2009 | 145 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 219 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 325 | 0.020 |
Why?
| | Myelin Proteins | 1 | 2008 | 45 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 394 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1995 | 1091 | 0.020 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
| | Lactic Acid | 1 | 2010 | 305 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 1995 | 927 | 0.020 |
Why?
| | Action Potentials | 1 | 2011 | 493 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 632 | 0.020 |
Why?
| | Parietal Lobe | 1 | 2008 | 58 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 332 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2009 | 137 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 812 | 0.020 |
Why?
| | Naproxen | 1 | 2007 | 17 | 0.020 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2007 | 9 | 0.020 |
Why?
| | Anticonvulsants | 1 | 2009 | 217 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2009 | 353 | 0.020 |
Why?
| | Endotoxemia | 1 | 2007 | 86 | 0.020 |
Why?
| | Mesentery | 2 | 1998 | 48 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 252 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2900 | 0.020 |
Why?
| | Gyrus Cinguli | 1 | 2006 | 86 | 0.020 |
Why?
| | Heart Rate | 1 | 1990 | 824 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2012 | 879 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 739 | 0.020 |
Why?
| | Thiocarbamates | 1 | 2005 | 6 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2007 | 196 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 52 | 0.010 |
Why?
| | Estrous Cycle | 1 | 2005 | 20 | 0.010 |
Why?
| | Locus Coeruleus | 1 | 2005 | 23 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 72 | 0.010 |
Why?
| | Phenotype | 2 | 2009 | 3196 | 0.010 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 2004 | 3 | 0.010 |
Why?
| | Pro-Opiomelanocortin | 1 | 2004 | 18 | 0.010 |
Why?
| | Motor Cortex | 1 | 2005 | 61 | 0.010 |
Why?
| | Metyrapone | 1 | 2004 | 2 | 0.010 |
Why?
| | Aminoglutethimide | 1 | 2004 | 5 | 0.010 |
Why?
| | Proline | 1 | 2005 | 79 | 0.010 |
Why?
| | Serotonin Agents | 1 | 2004 | 9 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 754 | 0.010 |
Why?
| | Reptilian Proteins | 1 | 2004 | 3 | 0.010 |
Why?
| | Rats, Mutant Strains | 1 | 2004 | 25 | 0.010 |
Why?
| | Group II Phospholipases A2 | 1 | 2004 | 9 | 0.010 |
Why?
| | Receptors, Leptin | 1 | 2004 | 23 | 0.010 |
Why?
| | Electrochemistry | 1 | 2004 | 78 | 0.010 |
Why?
| | HIV Infections | 1 | 1999 | 2837 | 0.010 |
Why?
| | Sleep | 1 | 2011 | 755 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2004 | 79 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1719 | 0.010 |
Why?
| | Catecholamines | 1 | 2004 | 98 | 0.010 |
Why?
| | Nanoparticles | 1 | 2010 | 482 | 0.010 |
Why?
| | Concanavalin A | 1 | 2003 | 76 | 0.010 |
Why?
| | Serotonin 5-HT1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 2003 | 5 | 0.010 |
Why?
| | Electrolysis | 1 | 2003 | 2 | 0.010 |
Why?
| | Immobilization | 1 | 2003 | 43 | 0.010 |
Why?
| | Sepsis | 1 | 2010 | 617 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2553 | 0.010 |
Why?
| | Blood Pressure | 1 | 1990 | 1789 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2189 | 0.010 |
Why?
| | Oxathiins | 1 | 2002 | 1 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2003 | 203 | 0.010 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2004 | 198 | 0.010 |
Why?
| | Drug Resistance | 1 | 2003 | 169 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 1984 | 143 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 1992 | 1239 | 0.010 |
Why?
| | Aniline Compounds | 1 | 2003 | 102 | 0.010 |
Why?
| | Physical Examination | 1 | 2003 | 241 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 1025 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 794 | 0.010 |
Why?
| | Wallerian Degeneration | 1 | 2001 | 1 | 0.010 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2001 | 5 | 0.010 |
Why?
| | Tachycardia | 1 | 1982 | 57 | 0.010 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2002 | 59 | 0.010 |
Why?
| | Epitopes | 1 | 2003 | 479 | 0.010 |
Why?
| | Emotions | 1 | 2006 | 551 | 0.010 |
Why?
| | Muscle Denervation | 1 | 2001 | 9 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2001 | 148 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2003 | 365 | 0.010 |
Why?
| | Immunoglobulin Isotypes | 1 | 2001 | 34 | 0.010 |
Why?
| | Luminescent Measurements | 1 | 2001 | 76 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 305 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2006 | 860 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2004 | 332 | 0.010 |
Why?
| | Spironolactone | 1 | 2001 | 36 | 0.010 |
Why?
| | Hypertrophy | 1 | 2001 | 133 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2005 | 394 | 0.010 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 198 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 312 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1775 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 40 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1998 | 32 | 0.010 |
Why?
| | Prognosis | 1 | 2007 | 4039 | 0.010 |
Why?
| | Administration, Oral | 1 | 2001 | 816 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1998 | 125 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1998 | 26 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 269 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 5136 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2001 | 1178 | 0.010 |
Why?
| | Butoxamine | 1 | 1996 | 1 | 0.010 |
Why?
| | Atenolol | 1 | 1996 | 7 | 0.010 |
Why?
| | Propranolol | 1 | 1996 | 50 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 45 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 1996 | 46 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1996 | 159 | 0.010 |
Why?
| | Diazepam | 1 | 1995 | 35 | 0.010 |
Why?
| | Anti-Anxiety Agents | 1 | 1995 | 46 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1995 | 109 | 0.010 |
Why?
| | Nylons | 1 | 1995 | 18 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 565 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 7623 | 0.010 |
Why?
| | Cytological Techniques | 1 | 1995 | 27 | 0.010 |
Why?
| | Jugular Veins | 1 | 1994 | 41 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1994 | 28 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 323 | 0.010 |
Why?
| | Methoxyflurane | 1 | 1993 | 2 | 0.010 |
Why?
| | Chloral Hydrate | 1 | 1993 | 3 | 0.010 |
Why?
| | Halothane | 1 | 1993 | 7 | 0.010 |
Why?
| | Pentobarbital | 1 | 1993 | 16 | 0.010 |
Why?
| | Xylazine | 1 | 1993 | 14 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1992 | 22 | 0.010 |
Why?
| | Cholesterol, Dietary | 1 | 1992 | 18 | 0.010 |
Why?
| | Cold Temperature | 1 | 1993 | 179 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 257 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 173 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1995 | 1142 | 0.010 |
Why?
| | Obesity | 1 | 2004 | 2993 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1992 | 955 | 0.010 |
Why?
| | Dietary Fats | 1 | 1992 | 304 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1984 | 27 | 0.000 |
Why?
| | Adolescent | 1 | 1982 | 21574 | 0.000 |
Why?
| | Aged | 1 | 1982 | 24001 | 0.000 |
Why?
| | Electrocardiography | 1 | 1984 | 629 | 0.000 |
Why?
| | Recurrence | 1 | 1984 | 1061 | 0.000 |
Why?
| | Middle Aged | 1 | 1982 | 33554 | 0.000 |
Why?
|
|
Watkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|